Department of Nuclear Medicine and Endocrine Oncology, M.Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.
Radiotherapy Department, M.Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.
Front Endocrinol (Lausanne). 2020 Oct 6;11:571421. doi: 10.3389/fendo.2020.571421. eCollection 2020.
We are witnessing a rapid worldwide increase in the incidence of papillary thyroid carcinoma (PTC) in the last thirty years. Extensive implementation of cancer screening and wide availability of neck ultrasound or other imaging studies is the main reason responsible for this phenomenon. It resulted in a detection of a growing number of clinically asymptomatic PTCs, mainly low-risk tumors, without any beneficial impact on survival. An indolent nature of low-risk PTC, particularly papillary thyroid microcarcinoma (PTMC), and the excellent outcomes raise an ongoing discussion regarding the adequacy of treatment applied. The question of whether PTMC is overtreated or not is currently completed by another, whether PTMC requires any treatment. Current ATA guidelines propose less extensive preoperative diagnostics and, if differentiated thyroid cancer is diagnosed, less aggressive surgical approach and limit indications for postoperative radioiodine therapy. However, in intrathyroidal PTMCs in the absence of lymph node or distant metastases, active surveillance may constitute alternative management with a low progression rate of 1%-5% and without any increase in the risk of poorer outcomes related to delayed surgery in patients, in whom it was necessary. This review summarizes the current knowledge and future perspectives of active surveillance in low-risk PTC.
在过去的三十年中,我们见证了全球范围内甲状腺乳头状癌 (PTC) 发病率的迅速上升。癌症筛查的广泛实施和颈部超声或其他成像研究的广泛应用是造成这种现象的主要原因。这导致越来越多的临床无症状 PTC 被发现,主要是低风险肿瘤,但对生存没有任何有益影响。低风险 PTC(尤其是甲状腺微小乳头状癌 [PTMC])的惰性性质和良好的预后引发了关于所应用治疗方法是否充分的持续讨论。PTMC 是否过度治疗的问题目前已被另一个问题所取代,即 PTMC 是否需要任何治疗。ATA 指南目前建议减少术前诊断的广泛程度,如果诊断为分化型甲状腺癌,则采用侵袭性较小的手术方法,并限制术后放射性碘治疗的适应证。然而,在没有淋巴结或远处转移的甲状腺内 PTMC 中,主动监测可能构成替代治疗方法,其进展率为 1%-5%,并且不会增加因延迟手术而导致预后较差的风险,在有必要手术的患者中,延迟手术不会增加预后较差的风险。本文综述了低风险 PTC 中主动监测的最新知识和未来前景。